Blood News and Research

RSS

Bayer HealthCare receives FDA approval for Stivarga to treat colorectal cancer

The U.S. Food and Drug Administration today approved Stivarga (regorafenib) to treat patients with colorectal cancer that has progressed after treatment and spread to other parts of the body (metastatic).

28 Sep 2012

First Edition: September 27, 2012

Today's headlines include reports about how the health law and Medicare are buzz words in public opinion polls and on the campaign trail.

27 Sep 2012

Report illustrates safety and efficacy of transoral robotic surgery for supraglottic laryngectomy

Robotic surgery though the mouth is a safe and effective way to remove tumors of the throat and voice box, according to a study by head and neck cancer surgeons at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

27 Sep 2012

Article reveals biochemical chain of events involved in penile erection

For two decades, scientists have known the biochemical factors that trigger penile erection, but not what's needed to maintain one. Now an article by Johns Hopkins researchers, scheduled to be published this week by the Proceedings of the National Academy of Sciences (PNAS), uncovers the biochemical chain of events involved in that process.

27 Sep 2012

GW to evaluate effectiveness of glucose-lowering drugs against type 2 diabetes

John Lachin, professor of biostatistics, epidemiology and statistics at the George Washington University, has been awarded a five-year, $134 million grant from the National Institute of Health's National Institute of Diabetes and Digestive and Kidney Diseases to conduct a clinical trial examining the long-term effectiveness of several glucose-lowering medications for treatment of people with type 2 diabetes. The grant sets a record as the largest sum award GW has ever received.

27 Sep 2012

KSU creates simple blood test that can accurately detect lung and breast cancer’s early stages

Researchers at Kansas State University have developed a simple blood test that can accurately detect the beginning stages of cancer.

27 Sep 2012

STENTYS announces European commercial release of new Self-Apposing stent technology

STENTYS, a medical technology company commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today the European commercial release of an enhanced stent-delivery system for its Self-Apposing stent.

27 Sep 2012

Karolinska Institutet scientists discover new approach to treat type II diabetes

An international team of scientists, led from Karolinska Institutet in Sweden, have discovered an entirely new approach to the treatment of type II diabetes. The therapy involves the blockade of signalling by a protein known as VEGF-B and this prevents fat from accumulating in the 'wrong' places, such as in muscles and in the heart. As a result the cells within these tissues are once again able to respond to insulin.

27 Sep 2012

CeQur completes PaQ Insulin Delivery Device clinical study on type 2 diabetes

CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced the completion of a clinical study with the company's PaQ Insulin Delivery Device.

27 Sep 2012

Positive results from Sobi, Biogen Idec's rFIXFc Phase 3 trial on hemophilia B

Biogen Idec and Swedish Orphan Biovitrum (Sobi) today announced positive results from B-LONG, a clinical study that evaluated a new long-lasting clotting factor candidate in people with hemophilia B. Hemophilia B is a rare inherited disorder that impairs blood coagulation.

27 Sep 2012

Adult stem cells can prevent Alzheimer's disease

In the first study of its kind, researchers at Korea's leading university and the RNL Bio Stem Cell Technology Institute announced this week the results of a study that suggests an astounding possibility: adult stem cells may not only have a positive effect on those suffering from Alzheimer's disease, they can prevent the disease.

27 Sep 2012

NBSTRN develops new tool for newborn screening researchers

After one-and-a-half years of intense development, end-user testing, a successful pilot, and through a contract to the American College of Medical Genetics and Genomics (ACMG) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the Newborn Screening Translational Research Network (NBSTRN) Coordinating Center has developed a centralized, web-based virtual repository of newborn dried blood spots (DBS) as an indispensable tool for newborn screening researchers.

27 Sep 2012

CSL develops new drug candidate against type 2 diabetes

CSL Limited has developed a new drug candidate that is able to prevent the development of type 2 diabetes and reverse its progression in animal models of the disease.

27 Sep 2012

Tight-junction proteins could help pin down hemorrhagic transformation risk

Study findings suggest that measuring levels of tight-junction proteins in the blood of patients with stroke may help to gauge their risk for hemorrhagic transformation.

26 Sep 2012

Increasing doses of radium chloride effective, tolerated in prostate cancer

Radium chloride treatment has dose-dependent beneficial effects on health outcomes in patients with castration-resistant prostate cancer and bone metastases, report researchers.

26 Sep 2012

The ABC of terminal hemorrhage management

To best cope with terminal hemorrhage, at-risk patients should be identified by healthcare professionals while their families and caregivers are prepared, supported, and instructed to assure, be there for, and calm and comfort the patient as the event occurs, say researchers.

26 Sep 2012

Blood test for monitoring Huntington’s disease may be possible in future

Measuring blood levels of mutant huntingtin protein may provide an alternative approach of determining the onset of Huntington’s disease in known carriers, researchers report.

26 Sep 2012

NOXXON commences NOX-A12 Phase IIa trial in relapsed MM

NOXXON Pharma today announced the treatment of the first cohort of three multiple myeloma (MM) patients in a Phase IIa clinical trial of its anti-CXCL12/SDF-1 (CXC chemokine ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer NOX-A12.

26 Sep 2012

Researchers characterize brain's immune response to infiltrating metastases

Brain metastases are common secondary complications of other types of cancer, particularly lung, breast and skin cancer. The body's own immune response in the brain is rendered powerless in the fight against these metastases by inflammatory reactions. Researchers at the MedUni Vienna have now, for the first time, precisely characterised the brain's immune response to infiltrating metastases. This could pave the way to the development of new, less aggressive treatment options.

26 Sep 2012

Geographic information system software offers new way to study human remains

A common type of geographic mapping software offers a new way to study human remains. In a recent issue of the American Journal of Physical Anthropology, researchers describe how they used commercially available mapping software to identify features inside a human foot bone - a new way to study human skeletal variation.

26 Sep 2012